by CheckRare Staff | Mar 1, 2022
James Howard Jr., MD, Distinguished Professor of Neuromuscular Disease and Professor of Neurology and Medicine at UNC School of Medicine, reviews the treatment landscape for myasthenia gravis. Myasthenia gravis is a chronic autoimmune neuromuscular disease...
by CheckRare Staff | Feb 28, 2022
David Weinstein, MD, Senior Vice President of Clinical Development at Passage Bio, discusses new interim clinical data from the Imagine-1 study of PBGM01, a gene therapy for GM1 gangliosidosis. This data was recently presented at WORLDSymposium 2022. GM1...
by CheckRare Staff | Feb 21, 2022
Stefan M. Schieke, MD, Assistant Professor of Dermatology at University of Wisconsin-Madison discusses cutaneous T-cell lymphoma (CTCL) in special populations such as African Americans and veterans of war. According to a paper published in U.S. Medicine, “The...
by CheckRare Staff | Feb 17, 2022
Jeffrey A. Zonder, MD, Hematologist-Oncologist from the Barbara Ann Karmanos Cancer Institute in Detroit, Michigan, describes the treatment landscape for patients with relapsed or refractory multiple myeloma. Multiple myeloma is a rare blood cancer associated...
by CheckRare Staff | Feb 15, 2022
David Birch, PhD, Scientific Director at the Retina Foundation of the Southwest, discusses phase 2/3 Sirius and Celeste clinical trials of investigational therapy, QR-421a, for people with USH2A-mediated retinitis pigmentosa and Usher syndrome. Retinitis...
